

Sen. Julie A. Morrison

Filed: 5/7/2024

	10300HB5405sam001 LRB103 37925 LNS 73018 a
1	AMENDMENT TO HOUSE BILL 5405
2	AMENDMENT NO Amend House Bill 5405 by replacing
3	everything after the enacting clause with the following:
4	"Section 5. The Department of Public Health Powers and
5	Duties Law of the Civil Administrative Code of Illinois is
6	amended by adding Section 2310-730 as follows:
7	(20 ILCS 2310/2310-730 new)
8	Sec. 2310-730. Diversity in clinical trials.
9	(a) As used in this Section, "underrepresented community"
10	or "underrepresented demographic group" means a community or
11	demographic group that is more likely to be historically
12	marginalized and less likely to be included in research and
13	clinical trials represented by race, ethnicity, sex, sexual
14	orientation, socioeconomic status, age, and geographic
15	location.
16	(b) Any State entity or hospital that receives funding

10300HB5405sam001

1	from the National Institutes of Health for the purpose of
2	conducting clinical trials of drugs or medical devices is
3	required to:
4	(1) adopt a policy that will result in the
5	identification and recruitment of persons who are members
6	of underrepresented demographic groups to participate in
7	the clinical trials and that:
8	(A) includes specific strategies for trial
9	enrollment and retention of diverse participants,
10	including, but not limited to, site location and
11	access, sustained community engagement, and reducing
12	burdens due to trial design or conduct, as
13	appropriate; and
14	(B) uses strategies recommended by the United
15	States Food and Drug Administration to identify and
16	recruit those persons to participate in the clinical
17	trials;
18	(2) provide information to trial participants in
19	languages other than English in accordance with current
20	federal requirements;
21	(3) provide translation services or bilingual staff
22	for trial recruitment and consent processes;
23	(4) provide culturally specific recruitment materials
24	alongside general enrollment materials; and
25	(5) provide remote consent options when not prohibited
26	by the granting entity or federal regulations.

10300HB5405sam001

1	(c) The Department, through voluntary reporting from
2	research institutions and in consultation with community-based
3	organizations and other stakeholders as appropriate and
4	available, shall analyze and provide recommendations on the
5	<u>following:</u>
6	(1) the demographic groups and populations that are
7	currently represented and underrepresented in clinical
8	trials in Illinois, including representation of groups
9	based on their geographic location;
10	(2) the barriers that prevent persons who are members
11	of underrepresented demographic groups from participating
12	in clinical trials in Illinois, including barriers related
13	to transportation; and
14	(3) approaches for how clinical trials can
14 15	(3) approaches for how clinical trials can successfully partner with community-based organizations
15	successfully partner with community-based organizations
15 16	successfully partner with community-based organizations and others to provide outreach to underrepresented
15 16 17	successfully partner with community-based organizations and others to provide outreach to underrepresented communities.
15 16 17 18	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and
15 16 17 18 19	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and post on its website the results of the analysis required under
15 16 17 18 19 20	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and post on its website the results of the analysis required under this subsection and any recommendations to increase diversity
15 16 17 18 19 20 21	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and post on its website the results of the analysis required under this subsection and any recommendations to increase diversity and reduce barriers for participants in clinical trials.
15 16 17 18 19 20 21 22	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and post on its website the results of the analysis required under this subsection and any recommendations to increase diversity and reduce barriers for participants in clinical trials. (d) The Department shall review the most recent guidance
15 16 17 18 19 20 21 22 23	successfully partner with community-based organizations and others to provide outreach to underrepresented communities. By July 1, 2026, the Department shall issue a report and post on its website the results of the analysis required under this subsection and any recommendations to increase diversity and reduce barriers for participants in clinical trials. (d) The Department shall review the most recent guidance on race and ethnicity data collection in clinical trials

1	(1) provides information concerning methods recognized
2	by the United States Food and Drug Administration for
3	identifying and recruiting persons who are members of
4	underrepresented demographic groups to participate in
5	clinical trials; and
6	(2) contains links to Internet websites maintained by
7	medical facilities, health authorities and other local
8	governmental entities, nonprofit organizations, and
9	scientific investigators and institutions that are
10	performing research relating to drugs or medical devices
11	in this State.
12	The Department may apply for grants from any source,
13	including, without limitation, the Federal Government, to fund
14	the requirements of this Section.".